Searched for
GLAXOSMITHKLINE PHARMACEUTICALS SHARE
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 26%Just look at developments in the past 48 hours. The war between Iran and Israel resumed, but within hours Tehran said it had halted all off...- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 22%As the market grappled with confusion over the Strait of Hormuz, there was more trouble for the bulls. After a few days of respite, another...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Glaxosmithkline Pharma Q1 Results: Net profit rises 8% to Rs 116 crore"Our results reflect good momentum across general medicines and vaccines during the quarter. We have delivered strong underlying growth wit...
- GlaxoSmithKline Pharma Q1 results: Net profit up 9% at Rs 121 croreConsolidated revenue from operations of the company stood at Rs 789.99 crore for the quarter under consideration. It was Rs 648.59 crore fo...
- GlaxoSmithKline Pharma Q4 results: Reports net profit of Rs 14 crIts consolidated revenue from operations stood at Rs 813.75 crore for the quarter under consideration. It was Rs 775.80 crore a year ago
- GlaxoSmithKline Pharma Q1 results: Net profit declines 2.38% to Rs 111 crThe company had posted a net profit of Rs 113.54 crore in the corresponding period previous fiscal, GlaxoSmithKline Pharmaceuticals said...
- GSK Pharma Q1 net profit up 35% at Rs 113.54 croreStandalone total income of the company also rose to Rs 818.78 crore for the quarter.
- GlaxoSmithKline Pharma Q2 net profit up 32% at Rs 130 croreThe company had posted a net profit of Rs 98.85 crore for the corresponding period of the previous fiscal.
- CCI approves Corona Remedies-GlaxoSmithKline dealDilo-BM, Dilo-DX, Stelbid and Vitneurin brands of GlaxoSmithKline would be acquired by Corona Remedies along with trademark and goodwill.
- GSK Pharma Q1 net down 23 per cent at Rs 72.27 croreThe company had posted a net profit of Rs 94.01 crore for the same period year ago, GlaxoSmithKline Pharmaceuticals said in a BSE filing.
- GlaxoSmithKline Pharma Q3 net profit declines 61% to Rs 45 croreGlaxoSmithKline Pharmaceuticals today reported a 61.24 per cent decline in its net profit at Rs 45.30 crore for the October-December period.
- GSK raises India unit stake to 75% via open offerWe are very pleased with the outcome of this transaction, which further increases our exposure to a strategically important market," GSK Ch...
- GSK Pharma shares slump over 8% ahead of closure of open offerShares of GlaxoSmithKline Pharmaceuticals slumped over 8 per cent as the open offer made by its UK-based parent to acquire additional stake...
- GSK gets FIPB nod to buy 24.33% more in indian armThe Singapore subsidiary of the UK-based GlaxoSmithKline plans to buy 24.33%stake, or 2.06 crore, equity shares in GlaxoSmithKline Pharmace...
- GSK's open offer for buying stake in Indian arm from February 7-21GlaxoSmithKline Plc's Rs 6,389.02 crore open offer to pick up 24.33 per cent stake in its Indian arm GlaxoSmithKline Pharma will start from...
- Buy GlaxoSmithKline Pharmaceuticals with a target of 2350: Ashwani GujralGlaxoSmithKline Pharmaceuticals Ltd is a ‘BUY’ call with a target of Rs 2350 and a stop loss of Rs 2200.
- GlaxoSmithKline net up 18 pc at Rs 136.74 croreGlaxoSmithKline Pharmaceuticals said its net profit rose by 18.18 per cent to Rs 136.74 crore for the quarter ended December 31, 2011.
- GlaxoSmithKline 2010 net profit up 10.37 pc to Rs 560.57 crThe company's board of director recommended a dividend of Rs 40 per share for the year ended December 31, 2010, in its meeting today.
Load More
